1	Full Title - Impact of Lactobacillus GG on weight loss in post-bariatric surgery
2	patients: a randomized, double-blind clinical trial
3	Short Title - Impact of Lactobacillus GG on weight loss in post-bariatric surgery patients
4	Authors: Myra Nasir ¹ , Samuel Stone ² , Ian Mahoney ³ , Justin Chang ⁴ , Julie Kim ⁵ , Sajani Shah ⁶ , Laura A.
5	McDermott ¹ , Paola Sebastiani ⁷ , Hocine Tighiouart ^{7,8} , David R. Snydman ¹ , Shira Doron ¹
6	Corresponding author: Myra Nasir
7	Email Address: myranasir1@gmail.com
8	Affiliations
9	1. Department of Medicine, Division of Geographic Medicine and Infectious Diseases, Tufts Medical
10	Center, Tufts University School of Medicine, Boston, MA, USA.
11	2. Department of Medicine, Division of Cardiology, Tufts Medical Center, Boston, MA, USA.
12	3. Department of Medicine, Division of Pulmonary Critical Care and Sleep Medicine, New York
13	University, New York, NY, USA.
14	4. Department of Surgery, Division of General Surgery, University of Illinois Chicago, Chicago, IL, USA.
15	5. Department of Surgery, Mount Auburn Hospital, Cambridge, MA, USA
16	6. Department of Surgery, Division of Bariatric Surgery, Tufts Medical Center, Boston, MA, USA
17	7. Department of Medicine, Institute for Clinical Research and Health Policy Studies, Tufts Medical
18	Center, Tufts University School of Medicine, Boston, MA, USA
19	8. Department of Medicine, Tufts Clinical and Translational Science Institute, Tufts University, Boston,
20	MA, USA.
21	

23 Abstract

Introduction and Objectives: There is increasing evidence suggesting the impact of human gut microbiota on 24 digestion and metabolism. It is hypothesized that the microbiome in obese subjects is more efficient than that in 25 lean subjects in absorbing energy from food, thus predisposing to weight gain. A transformation in gut 26 27 microbiota has been demonstrated in patients who have undergone bariatric surgery which has been positively associated with post-surgical weight loss. However, there is lack of studies investigating the impact of 28 probiotics on weight loss in post-bariatric surgery patients. The objectives of our study were to investigate the 29 30 impact of a probiotic, Lactobacillus GG (LGG), on weight loss and quality of life in patients who have undergone bariatric surgery. 31

Methods: The study was registered with ClinicalTrials.gov NCT01870544. Subjects were randomized to receive either LGG or placebo capsules. Percent total weight loss at their post-operative visits was calculated and differences between the two groups were tested using a t-test with unequal variances. The effect of LGG on Gastrointestinal Quality of Life Index (GIQLI) scores was estimated using a mixed model repeated measures model.

Results: The mean rate of change in percent total weight loss at the '30-day' post-operative visit for the placebo and treatment groups was 0.098 and 0.079 (p = 0.41), respectively, whereas that at the '90-day' post-operative visit was 0.148 and 0.126 (p = 0.18), respectively. The difference in GIQLI scores on '30-day' and '90-day' visits were 0.5 (-7.1, 8.0), p=0.91 and 3.7 (-4.9, 12.3), p=0.42, respectively. LGG was recovered from the stools of 3 out of 5 subjects in the treatment group.

42 Conclusion: We did not appreciate a significant difference in the mean rate of weight loss or GIQLI scores
43 between the groups who received LGG versus placebo. This study demonstrated survival of lactobacillus during
44 transit through the gastrointestinal tract.

45

46

47 Introduction

Obesity is a major public health problem worldwide. In the United States, 66% of the population is classified as
overweight or obese [1].

The 'microbiome revolution' has, in the last 20 years, brought our attention to the importance of human gut 50 microbiota as a factor affecting health and disease [2]. Gut microbiota include a range of microorganisms that 51 52 inhabit the gastrointestinal tract and have been implicated in digestion and metabolism, protection from 53 pathogens, insulin resistance and neurologic functioning [3-7]. Metagenomics and twin studies have revealed that certain microbial compositions are associated with lean body composition and alteration of these microbial 54 55 communities is associated with weight gain and metabolic disease [8,9]. In obese subjects, the flora of the gut 56 has been found to be less diverse, less rich and to have an increased ratio of Firmicutes to Bacteroidetes as 57 compared to normal weight individuals [10]. It is hypothesized that the obese microbiome is more efficient than 58 the lean microbiome in absorbing energy from food, thus predisposing to weight gain [8].

59 Bariatric surgery is the most effective treatment for the achievement of prolonged weight loss and has been 60 associated with improvement in diabetes and hypertension [11-12]. Studies suggest that the beneficial health effects of these surgeries are not only explained by procedure-induced food restriction and malabsorption but 61 also by alterations of neuroendocrine and immune signaling pathways [13]. An increase in Bacteroidetes and 62 Proteobacteria with a decrease in Firmicutes after bariatric surgery has been demonstrated. When the 63 Bacteroidetes/Firmicutes ratio after bariatric procedures was used as surrogate marker for the observed changes 64 in the obese microbiome compared to the lean microbiome, it was positively associated with post-surgical 65 66 weight loss [14].

Lactobacillus strain GG (LGG) is a widely studied probiotic, especially with regards to its influence on
metabolic syndrome. A favorable impact on obesity and diabetes has been demonstrated in mice with dietinduced obesity showing evidence of improvement in insulin resistance with LGG [15,16].

70 Whereas there is increasing evidence to suggest that use of probiotics is linked with lower inflammatory state

and weight loss, there is a lack of studies investigating the impact of probiotics on weight loss in patients who

have undergone bariatric surgery [17-19].

We conducted a pilot trial to investigate the impact of LGG on weight loss in patients who have undergone
bariatric surgery.

75 *Methods*

This was a randomized, double-blind placebo-controlled pilot trial to investigate whether weight loss and changes in quality of life differ after bariatric surgery in patients who did and did not receive LGG. The primary outcome is the rate of change of percent total weight loss. Secondary outcomes are Gastrointestinal Quality of Life Index (GIQLI) at day of surgery, at 30-day visit and at 90-day visit, adverse event percentages and recovery of LGG from stool.

81 Study population

82 Subjects were recruited from Tufts Medical Center in Boston, Massachusetts, USA, from June 24, 2013 to January 31, 2016, if they were scheduled for elective gastric surgery for weight reduction. Patients were eligible 83 for the study if they were at least 18 years of age, were evaluated for surgery as outpatients, and had stable 84 85 comorbidities. Exclusion criteria included active colitis: recent or planned receipt of radiation or chemotherapy: being on active immunosuppressive medication; known or suspected allergies to probiotics, lactobacillus, milk 86 protein, or microcrystalline cellulose, or allergy to 2 or more of the rescue antibiotics that might be used to treat 87 Lactobacillus infection (ampicillin, clindamycin and moxifloxacin) should that become necessary; and positive 88 89 baseline stool culture for LGG.

90 Subjects included in the study were restricted from consuming certain yogurts, however since yogurt is a dietary 91 staple after bariatric surgery, to improve enrollment after initial slow accrual, the protocol was later amended to 92 allow for types of yogurt that contained select live cultures that would be expected to have minimal effect on

patients' microbiota, as well as yogurt without cultures. The four commercially available yogurts that were
 permitted were Yoplait Greek, Brever's light, Brown Cow Fat Free Greek and Brown Cow Greek.

Study patients undergoing sleeve gastrectomy were initially planned to be excluded from the study. However,
sleeve gastrectomy rapidly became the preferred weight-loss surgery which resulted in significantly fewer
gastric bypass surgeries at Tufts Medical Center than they were at the time of initial study design. Therefore, in
order to improve enrollment, the study design was amended to included patients undergoing sleeve gastrectomy,
in addition to gastric bypass surgery.

100

101 Trial Design and Oversight

102 The trial design is parallel with an allocation ratio of 1:1. Sample size analysis was not conducted since this was103 a pilot study to inform a future larger scale trial.

The random allocation was done by the statistician using a random number generator with the allocation 104 sequence provided directly to the research pharmacy who labeled the pills with the subject names but without 105 identification of the compound. Study staff, which included investigators and research assistants, enrolled 106 subjects and went to the research pharmacy to pick up the study compound already labeled for the subject. 107 Thus, investigators, study staff and participants were blinded, as were the clinical staff caring for these subjects. 108 Subjects were randomized to receive either probiotic capsules of LGG ($1x10^{10}$ organisms per capsule) or 109 identical appearing placebo capsules provided by Martek, manufactured by Chr Hansen, Inc., to be taken twice 110 daily for 44 days, beginning 14 days before surgery. Pill bottles contained 100 capsules. Capsules were 111 112 collected from each subject prior to initiation of the course and at study completion. One capsule from each time period was cultured to confirm viability of the organism and organism counts. Ten extra capsules were 113 provided in case of loss of capsules. Remaining capsules were counted at the end of the study period to assess 114 115 adherence. Stool samples were obtained at baseline (2-4 weeks before surgery), on the day of surgery and at '30-day' and '90-day' post-operative visits to assess for the presence of colonization by LGG. 116

To monitor for adverse events, subjects completed questionnaires about the presence or absence of certain symptoms before and after they began taking the study compound. These questionnaires were completed at the first surgeon visit, first pre-operative visit, and day of surgery in order to establish a baseline, then at the first four weekly post-operative telephone check-ins, '30-day' post-operative visit and '90-day' post-operative visit.

121 All subjects received routine pre-operative prophylactic antibiotics to prevent surgical site infection. One

subject in the placebo group was receiving azithromycin pre-operatively for suspected bacterial infection and

123 continued it for several days after surgery.

124 The study was registered with ClinicalTrials.gov NCT01870544, and was approved by the Tufts Medical Center

125 Institutional Review Board. A written informed consent was taken from all subjects. CONSORT reporting

126 guidelines were used (S1 CONSORT Checklist) [20].

127 Data collection

Demographic information, history of chronic diseases, and medications were collected at screening. Participants were asked to complete the validated GIQLI questionnaire at the pre-operative visit, on the day of surgery, and at the post-operative visits closest to 30 and 90 days after surgery [21]. Study weight measurements were taken at the preoperative visit, the day of surgery, and at the visits closest to 30 and 90 days after surgery. Since these visits did not necessarily occur on post-op days 30 and 90, we refer to them throughout this manuscript as the '30-day' and '90-day' visits in quotation marks. Weights were also extracted from the electronic medical record when available from visits not part of the study.

135 Statistical analysis of clinical outcomes

136 Compared to other metrics such as excess weight loss and change in body mass index, percent total weight loss

137 (%TWL) has been found to have the least variability when stratified by preoperative patient characteristics, and

therefore is the metric used in this study [22]. Subject weights were measured during post-operative visits.

139 Percent total weight loss at X days (%TWL_X) was calculated as (weight at surgery – weight at visit)/ weight at

140 surgery x X/(delta day), where delta day was the difference in days between the date of surgery and the date of

141 visit. Differences in %TWL_X between the two groups were tested using a t-test with unequal variances.

142 Sample collection

143 Subjects were given stool collection kits consisting of a toilet hat, gloves, tongue depressors, specimen cups and

paper bags and asked to produce and save a stool sample in their freezer within 24 hours of their appointment

145 date and to bring the sample to their scheduled visit. Samples were then aliquoted and frozen at -80°C.

146 Isolation of LGG from Capsule and Stool samples

Stool samples and capsules were serially diluted and plated in duplicate onto Lactobacilli selective agar (BBL) 147 supplemented with tomato juice and glacial acetic acid. Plates were incubated for 48 hours in an anaerobic 148 chamber (5%CO₂, 10%H₂, 85% N₂) at 35 ⁺/- 2° C and were then observed for characteristic growth and colonial 149 morphology. Presumptive LGG colonies, appearing as white and creamy with a distinct buttery smell, were 150 enumerated. The palisading appearance of LGG colonies on Gram stain was used to distinguish it from other 151 Lactobacillus species. All strains presumptively identified were run through the APIZYM® (Biomerieux), an 152 identification kit that differentiates between the Lactobacillus species on the basis of enzymatic reactions. 153 Isolates that were consistent with LGG by APIZYM® were additionally run through the API CH-50 ® 154 (Biomerieux) system, which differentiates between different species of Lactobacillus on the basis of 155 carbohydrate fermentation. 156

157 Statistical analysis of Gastrointestinal Quality of Life Index (GIQLI) scores

158 The effect of LGG on the continuous GIQLI scores was estimated using a mixed model repeated measures

159 model. The outcome for each subject consisted of all follow-up measurements including the baseline

160 measurement. All variables included in the model were treated as fixed effects and included categorical time,

161 randomization and their interaction. We performed sensitivity analyses to account for missing data in follow-up

using pattern mixture models (PMM). We used the core functionality available in SAS PROC MI and
 MIANALYZE procedures to implement two types of PMM: standard PMM and control-based PMM.

164

165

166 *Results*

167 A total of 37 bariatric surgery candidates were recruited and followed up through April 2016. Of these, 15 subjects withdrew prior to randomization, 3 after randomization and before study drug was administered and 1 168 who received study drug but was lost to follow up, with 18 subjects completing follow-up (Figure 1). Ten 169 subjects received oral placebo and 8 received oral LGG. Table 1 compares the characteristics of subjects by 170 study group. The median age of the placebo group and the treatment group was 47.5 and 46.5, respectively. Out 171 of 18 subjects, 12 were female, comprising 60% of the placebo group and 75% of the treatment group. Of those 172 who received LGG, compliance was variable and ranged between 0 and 19 doses missed. Baseline median body 173 mass index (BMI) and excess weight of the placebo group (42.44 and 13.02 lbs, respectively) were comparable 174 to the baseline median BMI and excess weight of the treatment group (41.16 and 102.28 lbs). The placebo 175 group, as compared to the treatment group, had a higher percentage of patients with diabetes (40% vs. 25%, 176 respectively) and a lower percentage of patients with hyperlipidemia (20% vs. 25%, respectively). Most 177 subjects underwent sleeve gastrectomy (70% and 75% for placebo and treatment groups, respectively) while the 178 rest underwent roux-en-y gastric bypass. 179 At baseline, mean (SD) GIOLI scores for treatment and placebo groups were 59.0 (6.1) and 59.4 180

181 (7.2) respectively. On the day of surgery, GIQLI score was 61.1 (6.3) for the treatment group as

compared to 57.4 (9.2) for the placebo group with a mean difference (95%CI) of 3.7 (-3.8, 11.2),

183 p=0.35. At the '30-day' post-operative visit, GIQLI score was 55.1 (8.5) for the treatment group as compared

- to 55.5 (4.0) for the placebo group with a difference of 0.5 (-7.1, 8.0), p=0.91. At the '90-day' post-operative
- visit GIQLI score was 60.7 (4.9) for the treatment group as compared to 56.5 (6.8) for the placebo
- 186 group with a difference of 3.7 (-4.9, 12.3), p=0.42.
- 187
- 188 Figure 1. Flowchart of subject selection
- 189 RYGB: Roux-en-y gastric bypass

190	Table 1	: Characteri	stics of th	e study	population
-----	---------	--------------	-------------	---------	------------

	N = 10	N = 8
Characteristic	Placebo	Treatment
Age, median (IQR), y	47.5 (40.75 - 49.75)	46.5 (40.0 - 53.0)
Female, No. (%)	6 (60%)	6 (75%)
BMI, median (IQR)	42.44 (41.52 - 45.80)	41.16 (40.14 - 42.96)
Diabetes, No. (%)	4 (40%)	2 (25%)
Hyperlipidemia, No. (%)	2 (20%)	2 (25%)
Excess Weight, median (IQR), lbs.	103.02 (99.79 – 127.13)	102.28 (86.60 - 120.54)
Quality of Life score, mean (SD)	59.0 (6.1)	59.4 (7.2)
Surgery Type		
Roux-en-y gastric bypass, No. (%)	3 (30%)	2 (25%)
Sleeve gastrectomy, No. (%)	7 (70%)	6 (75%)

191

192 The mean time between surgery and the '30-day' post-operative visit for the treatment and placebo groups was

193 34 and 54 days, with a median of 38 and 48 days, respectively. The mean time between surgery and the '90-

day' post-operative visit for the treatment and placebo groups was 105 and 125 days, with a median of 107 and

195 111 days, respectively. The mean rate of change in percent of total weight loss (%TWL) at the '30-day' post-

operative visit for the placebo and treatment groups was 0.098 and 0.079 (p = 0.41), respectively, whereas that

197 at the '90-day' post-operative visit was 0.148 and 0.126 (p = 0.18), respectively.

198 LGG was not recovered from any stool samples from subjects belonging to the placebo group. Among subjects

in the treatment group, no samples were successfully obtained after completion of the course of treatment. All

- samples were taken during the treatment course. Stool samples were collected from only 5 of the 8 subjects in
- 201 the treatment group after the start of the course of treatment. Of the 5, LGG was recovered from the stool
- samples of 3 subjects. One of the subjects from whom LGG was not recovered was later found to have missed
- 203 19 doses, and the other 4 doses.
- 204 The most common adverse events experienced by the study and placebo groups while taking the study
- 205 compound were increased frequency of bowel movements, loss in appetite, flatulence, constipation, rumbling,
- looser stools, and abdominal fullness (Table 22).

Table 22: Adverse events reported by subjects while taking study compound

Adverse events	Study	Placebo
	group	group
Increased frequency of bowel	6	8
movements		
Loss in appetite	6	7
Flatulence	6	7
Constipation	7	5
Rumbling	3	7

Looser stools	5	6
Abdominal fullness	5	6
Burping/belching	4	6
Abdominal pain	4	2
Bloating	3	2
Nausea	3	2
Urgent bowel movements	2	3
Trouble swallowing food	1	3
Other illnesses	3	1
Heartburn	0	3
Fevers/chills	1	2
Blood in stool	2	1
Hospitalization	2	0
Increased gas	1	1
Fluid coming up in the mouth	0	1

209

210

211 Discussion

Growing evidence supports that weight-loss interventions, whether dietary or surgical, lead to changes in the

composition of the gastrointestinal microbiome [23]. However, there are conflicting data regarding the impact

of probiotics on weight loss. Whereas Kadooka et al demonstrated a significant decrease in weight and body fat

in subjects who received fermented milk with lactobacillus compared to a control group [24], a meta-analysis
by Mohammadi et al of 9 randomized controlled trials including 410 subjects showed no significant difference
in BMI or percentage of excess weight loss between the probiotic and control groups [25].

In our pilot study of patients who underwent bariatric surgery, we did not appreciate a clinical or statistically 218 significant difference in the mean rate of weight loss between the groups who received LGG versus placebo. 219 Our study findings are in keeping with results demonstrated by a systematic review and meta-analysis of 5 220 randomized controlled trials including a total of 279 patients after bariatric surgery in which no significant 221 difference in percent excess weight loss at 3 months, change in BMI, waist circumference change or fat mass 222 change was noted between the probiotic and placebo groups [26]. However, it should be noted that if there were 223 some minor impact of oral probiotics on weight loss, this may be masked by the substantial effect of bariatric 224 surgery on weight loss, resulting in no measurable difference between the two groups. 225

This is the first study to our knowledge to evaluate whether probiotics can be recovered in the stool of patients 226 who have undergone bariatric surgery. To exert its beneficial properties, probiotics must survive during their 227 transit through the low pH environment of the stomach and lytic enzymes present in the small intestine. In our 228 study, LGG was recovered from 3 of 5 subjects in the treatment group, demonstrating survival, though 229 230 inconsistent, of the lactobacillus during transit through the gastrointestinal tract. Several factors may have contributed to the lack of recovery of LGG from 2 subjects in the treatment group who were still in the 231 treatment phase, including adherence, the constituents of the subjects' diet which can affect survival and growth 232 233 of the bacteria, the stability of the culture and size of the inoculum which affect the survival of probiotic bacteria. 234

There was no significant difference in the GIQLI scores within the follow-up period, between the study andplacebo groups.

In our pilot study of patients undergoing bariatric surgery, LGG was found to be safe. Adverse event rates were similar in the two groups, and consistent with what would be expected in patients who have undergone

239 gastrointestinal surgery.

Our study had several limitations. It was a pilot and therefore not intended to be fully powered to detect statistically significant differences in outcomes between groups. Though the follow-up outpatient visits were intended to be at 1- and 3- months post-surgery, there was significant variability in the number of days after surgery at which subjects were evaluated. The 3-month duration of follow-up may not have been long enough to demonstrate a clinically significant difference in weight loss or quality of life scores between the two groups.

245

246 REFERENCES


- Wang Y, Beydoun MA, Liang L, Caballero B, Kumanyika SK. Will all Americans become overweight or
 obese? Estimating the progression and cost of the US obesity epidemic. *Obesity*. 2008.
 doi:10.1038/oby.2008.351
- Petersen JM, Osvatic J. Microbiomes In Natura : Importance of Invertebrates in Understanding the
 Natural Variety of Animal-Microbe Interactions . *mSystems*. 2018. doi:10.1128/msystems.00179-17
- Rothschild D, Weissbrod O, Barkan E, Kurilshikov A, Korem T, Zeevi D, et al. Environment dominates
 over host genetics in shaping human gut microbiota. *Nature*. 2018. doi:10.1038/nature25973
- 4. Mills S, Stanton C, Lane JA, Smith GJ, Ross RP. Precision nutrition and the microbiome, part I: Current
 state of the science. *Nutrients*. 2019. doi:10.3390/nu11040923
- 5. Kelly CJ, Zheng L, Campbell EL, Saeedi B, Scholz C, Bayless A, et al. Crosstalk between microbiota-
- derived short-chain fatty acids and intestinal epithelial HIF augments tissue barrier function. *Cell Host*
- 259 *Microbe*. 2015. doi:10.1016/j.chom.2015.03.005

- 260 6. Zheng P, Zeng B, Liu M, Chen J, Pan J, Han Yu, et al. The gut microbiome from patients with
- schizophrenia modulates the glutamate-glutamine-GABA cycle and schizophrenia-relevant behaviors in
 mice. *Sci Adv.* 2019. doi:10.1126/sciadv.aau8317
- 7. Kelly JR, Kennedy PJ, Cryan JF, Dinan TG, Clarke G, Hyland NP. Breaking down the barriers: The gut
 microbiome, intestinal permeability and stress-related psychiatric disorders. *Front Cell Neurosci*. 2015.
 doi:10.3389/fncel.2015.00392
- Turnbaugh PJ, Gordon JI. The core gut microbiome, energy balance and obesity. In: *Journal of Physiology*. ; 2009. doi:10.1113/jphysiol.2009.174136
- Turnbaugh PJ, Hamady M, Yatsunenko T, Cantarel B, Duncan A, Ley R, et al. A core gut microbiome in
 obese and lean twins. *Nature*. 2009. doi:10.1038/nature07540
- 10. Ley RE, Bäckhed F, Turnbaugh P, Lozupone CA, Knight RD, Gordon JI. Obesity alters gut microbial
 ecology. *Proc Natl Acad Sci U S A*. 2005. doi:10.1073/pnas.0504978102
- Tadross JA, Le Roux CW. The mechanisms of weight loss after bariatric surgery. *Int J Obes*. 2009.
 doi:10.1038/ijo.2009.14
- Federico A, Dallio M, Tolone S, Gravina AG, Patrone V, Romano M, et al. Gastrointestinal hormones,
 intestinal microbiota and metabolic homeostasis in obese patients: Effect of bariatric surgery. *In Vivo;*2016; 30(3), 321–330.
- Ionut V, Bergman RN. Mechanisms responsible for excess weight loss after bariatric surgery. *J Diabetes Sci Technol.* 2011. doi:10.1177/193229681100500536
- Luijten JCHBM, Vugts G, Nieuwenhuijzen GAP, Luyer MDP. The Importance of the Microbiome in
 Bariatric Surgery: a Systematic Review. *Obes Surg.* 2019. doi:10.1007/s11695-019-03863-y
- Ji Y, Park S, Park H, Hwang E,Shin H, Pot B, et al. Modulation of active gut microbiota by Lactobacillus
 rhamnosus GG in a diet induced obesity murine model. *Front Microbiol*. 2018.

- 283 doi:10.3389/fmicb.2018.00710
- 16. Kim SW, Park KY, Kim B, Kim E, Hyun CK. Lactobacillus rhamnosus GG improves insulin sensitivity
 and reduces adiposity in high-fat diet-fed mice through enhancement of adiponectin production. *Biochem Biophys Res Commun.* 2013. doi:10.1016/j.bbrc.2012.12.121
- 17. Hegazy SK, El-Bedewy MM. Effect of probiotics on pro-inflammatory cytokines and NF-κb activation
 in ulcerative colitis. *World J Gastroenterol*. 2010. doi:10.3748/wjg.v16.i33.4145
- 18. Ashraf R, Shah NP. Immune System Stimulation by Probiotic Microorganisms. *Crit Rev Food Sci Nutr.*2014. doi:10.1080/10408398.2011.619671
- 19. Dror T, Dickstein Y, Dubourg G, Paul M. Microbiota manipulation for weight change. *Microb Pathog*.
 2017. doi:10.1016/j.micpath.2016.01.002
- 20. Schulz KF, Altman DG, Moher D, for the CONSORT Group. CONSORT 2010 Statement: updated
 guidelines for reporting parallel group randomised trials
- 295 21. Eypasch E, Williams JI, Wood-Dauphinee S, Ure BM, Schmulling C, Neugebauer E, et al.
- Gastrointestinal Quality of Life Index: Development, validation and application of a new instrument. *Br J* Surg. 1995. doi:10.1002/bjs.1800820229
- 298 22. Grover BT, Morell MC, Kothari SN, Borgert AJ, Kallies KJ, Baker MT. Defining Weight Loss After
- Bariatric Surgery: a Call for Standardization. *Obes Surg*. 2019. doi:10.1007/s11695-019-04022-z
- 300 23. Seganfredo FB, Blume CA, Moehlecke M, Giongo A, Casagrande DS, Spolidoro JVN, et al. Weight-loss
- 301 interventions and gut microbiota changes in overweight and obese patients: a systematic review. Obes
- 302 *Rev.* 2017. doi:10.1111/obr.12541
- 24. Kadooka Y, Sato M, Ogawa A, Miyoshi M, Uenishi H, Ogawa H, et al. Effect of Lactobacillus gasseri
- 304 SBT2055 in fermented milk on abdominal adiposity in adults in a randomised controlled trial. *Br J Nutr*.
- 305 2013. doi:10.1017/S0007114513001037

306	25.	Mohammadi H, Ghavami A, Hadi A, Askari G, Symonds M, Miraghajani M. Effects of pro-/synbiotic
307		supplementation on anthropometric and metabolic indices in overweight or obese children and
308		adolescents: A systematic review and meta-analysis. Complement Ther Med. 2019.
309		doi:10.1016/j.ctim.2019.05.008
310	26.	Daghmouri MA, Chaouch MA, Yang W, Akremi S, Jaoua H, Fadhel KB, et al. Probiotics in bariatric
311		surgery ensure greater lipids and glycemic profile with no effect on anthropometric measurements and
312		inflammatory markers: A systematic review and meta-analysis of RCT. Surg Open Dig Adv.
313		2022;7:100061. doi:10.1016/j.soda.2022.100061
314		
315	Fun	ding
316	This	study was supported by a grant from Tufts University Collaborates and NIH CTSA grant UM1TR004383
317	and UM1TR004398 awarded to SD, JK and DS.	
318	S1 C	ONSORT Checklist

319 S2 Appendix. Study Protocol



Figure